Metformin hydrochloride
( DrugBank: Metformin, Metformin hydrochloride / KEGG DRUG: Metformin hydrochloride, Metformin, Metformin hydrochloride, Metformin )
5 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
81 | 先天性副腎皮質酵素欠損症 | 1 |
158 | 結節性硬化症 | 1 |
265 | 脂肪萎縮症 | 1 |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 102 / 薬物数 : 72 - (DrugBank : 18) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 71
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
158. 結節性硬化症
臨床試験数 : 129 / 薬物数 : 56 - (DrugBank : 20) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 116
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
265. 脂肪萎縮症
臨床試験数 : 127 / 薬物数 : 137 - (DrugBank : 58) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 99
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
299. 嚢胞性線維症
臨床試験数 : 1,826 / 薬物数 : 1,271 - (DrugBank : 246) / 標的遺伝子数 : 118 - 標的パスウェイ数 : 180
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
301. 黄斑ジストロフィー
臨床試験数 : 59 / 薬物数 : 42 - (DrugBank : 14) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 72
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|